Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
454.50
+6.12 (1.37%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 448.04 - 460.12
52 week 269.50 - 495.50
Open 449.48
Vol / Avg. 856,036.00/918,298.00
Mkt cap 45.73B
P/E 147.91
Div/yield     -
EPS 3.07
Shares 100.65M
Beta 0.88
Inst. own 73%
May 12, 2015
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting - 10:30AM EDT - Add to calendar
May 6, 2015
Q1 2015 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 11, 2015
Regeneron Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 3, 2015
Regeneron Pharmaceuticals Inc at Cowen Health Care Conference -Breakout Session
Mar 3, 2015
Regeneron Pharmaceuticals Inc at Cowen Health Care Conference
Feb 24, 2015
Regeneron Pharmaceuticals Inc at RBC Healthcare Conference
Feb 10, 2015
Q4 2014 Regeneron Pharmaceuticals Inc Earnings Release
Feb 10, 2015
Q4 2014 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
Jan 13, 2015
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference Q&A session
Jan 13, 2015
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 13.73% 12.34%
Operating margin 28.00% 28.55%
EBITD margin - 31.60%
Return on average assets 11.61% 10.20%
Return on average equity 17.35% 15.49%
Employees 2,925 -
CDP Score - -

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron develops new product candidate using VelociSuite technology platforms. Regeneron�s discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Company�s VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. The Company also has human monoclonal antibody technology, VelocImmune and cell line expression technology VelociMab. Regeneron�s antibody product candidates in clinical trials were developed using VelocImmune. The Company has three marketed products: EYLEA, ZALTRAP and ARCALYST.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 84
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 50
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 41
Bio & Compensation  - Reuters
Murray A. Goldberg Senior Vice President - Administration, Assistant Secretary
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 57
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Senior Vice President - Research and Development Sciences
Age: 57
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 54
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 54
Bio & Compensation  - Reuters